Providing for patient access to diagnostics and treatments for Lyme disease and related tick-borne illnesses; and requiring health care policies to provide certain coverage.
Summary
SB 461, the Lyme Disease and Related Tick-Borne Illness Diagnosis and Treatment Act, would require health insurance policies and certain government programs in Pennsylvania to cover diagnostic testing, tick testing, and prescribed treatment for Lyme disease and related tick-borne illnesses when ordered by a licensed health care practitioner. The bill specifically directs coverage for all bands on the western blot test when used for a clinical diagnosis, and it allows treatment plans to include short-term or long-term antibiotic or antimicrobial therapy, including oral or intravenous treatment, if documented in the patient’s medical record.
The bill also creates a statewide registry and educational framework. The Department of Health would be required to run an annual public information campaign, distribute culturally and linguistically appropriate educational materials, and partner with the Tick Research Lab of Pennsylvania to develop an electronic database containing nonidentifiable tick-testing and diagnosis information. The act would take effect 60 days after enactment, and insurers would have to report to the Insurance Department by January 1, 2027 on implementation of the coverage requirements.
Impact
SB 461 would amend the practical scope of health coverage in Pennsylvania by mandating insurance and government-program coverage for Lyme disease and related tick-borne illness diagnostics and treatments, including broader testing and potentially longer courses of antibiotics than are often covered under standard policies. It would affect private health insurers, Medicaid, CHIP, and covered persons/enrollees seeking care for these conditions, while also requiring the Department of Health and insurers to take on new reporting, education, and regulatory duties. The bill does not eliminate cost-sharing, but it requires the new benefits to be treated like other covered medical services and authorizes the department to promulgate regulations to administer the act.
Sentiment
The available voting history suggests strong support in committee: the Senate Health and Human Services Committee reported the bill as committed on a 12-0 vote. The bill’s findings and purpose sections frame Lyme disease as a major public health problem in Pennsylvania, and the legislation is presented as a patient-access and education measure rather than a cost-containment measure. No committee transcript is available in the provided materials, so the record shows broad procedural support but limited public debate in the supplied context.
Contention
The main points of potential contention are the bill’s coverage of longer-term antibiotic or antimicrobial treatment, its inclusion of all western blot bands for clinical diagnosis, and its reliance on a clinical-diagnosis standard that may differ from narrower surveillance criteria used in public health reporting. Insurers may also be concerned about utilization, medical-necessity standards, and administrative costs associated with expanded coverage and reporting. On the other hand, supporters appear focused on improving access for patients with persistent or complex symptoms and on recognizing that standard surveillance definitions may not capture all clinically diagnosed cases.
Requires health insurers to provide coverage for long term medical care for Lyme disease and other tick borne related pathogens; provides for taxpayer gifts for tick borne illness research, detection and education; establishes the tick borne illness research, detection and education fund.